inxmed limited

Private

Last Round

Series C

Aug 22, 2025

Last Round Size

$34M

Est. Valuation

$306M

Total Funding Raised

$134M

Company Overview

Developer of cancer therapeutics targeting drug resistance and the stroma microenvironment for hard-to-treat solid tumors.

Historical view of private secondary pricing and transaction trends.

Proprietary index based on bid/ask volume and sentiment.

Track how buyer interest and sentiment changes over time.

Related companies by embedding similarity.

Access detailed peer comparisons, multiples, and valuation benchmarks.

Historical fundraising activity

SEC and related filings with document metadata.

Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

SEC and related filings with document metadata.

Common questions about inxmed limited's valuation, stock price, and market status.

Headquarters—

Year Founded2017

Last FundingAug 22, 2025

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.